{"nctId":"NCT00414050","briefTitle":"A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)","startDateStruct":{"date":"2006-10-06","type":"ACTUAL"},"conditions":["Hepatitis B"],"count":1718,"armGroups":[{"label":"Modified Process Hepatitis B vaccine 5 μg","type":"EXPERIMENTAL","interventionNames":["Biological: Modified Process Hepatitis B Vaccine (Experimental)"]},{"label":"RECOMBIVAX HB™ Hepatitis B Vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Hepatitis B Vaccine (Recombinant)"]},{"label":"Modified Process Hepatitis B vaccine 10 μg","type":"EXPERIMENTAL","interventionNames":["Biological: Modified Process Hepatitis B Vaccine (Experimental)"]},{"label":"ENGERIX-B®","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Hepatitis B Vaccine (Recombinant)"]}],"interventions":[{"name":"Modified Process Hepatitis B Vaccine (Experimental)","otherNames":[]},{"name":"Hepatitis B Vaccine (Recombinant)","otherNames":["RECOMBIVAX HB™"]},{"name":"Hepatitis B Vaccine (Recombinant)","otherNames":["ENGERIX-B®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant is a healthy infant approximately 2 months of age\n\nExclusion Criteria:\n\n* Birth mother is a known carrier of hepatitis B virus or another known carrier has lived in close contact with the participant\n* Participant's birth mother did not receive any prenatal care\n* Participant has previous history of hepatitis B infection\n* Participant has been vaccinated against hepatitis B or birth mother was vaccinated within 6 months before birth of participant\n* Participant has had a fever within 72 hours of study start\n* Participant has received any blood-derived product or birth mother received blood-derived product within 6 months of birth of participant","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Months","maximumAge":"2 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Seroresponders to the Modified Process Hepatitis B Vaccine (5 μg and 10 μg Dose), RECOMBIVAX HB™ Hepatitis B Vaccine (Currently Licensed Vaccine), and ENGERIX-B®","description":"The percentage of participants as measured by Seroresponse. Seroresponse was defined as anti-hepatitis B surface antibodies greater than or equal to 10 milli-International Units (mIU)/mL. Success on the primary immunogenicity hypothesis required demonstrating an adequate anti-HBs seroprotection rate response for either modified process hepatitis B 5 μg vaccine or RECOMBIVAX HB™. Specifically, the lower bound of the multiplicity adjusted 95% confidence interval (CI) on the seroprotection rate for either vaccine was required to be above 90.0%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"98.5","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"99.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody to Hepatitis B Surface Antigen Geometric Mean Titer (Anti-HBs GMT) Responses for Modified Process Vaccine (5 μg and 10 μg), RECOMBIVAX™ Hepatitis B (Currently Licensed Vaccine), and ENGERIX-B®","description":"Geometric Mean Titer - Antibody titer is a laboratory test that measures the presence and amount of antibodies in blood.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"748.2","spread":null},{"groupId":"OG001","value":"376.8","spread":null},{"groupId":"OG002","value":"981.5","spread":null},{"groupId":"OG003","value":"556.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":430},"commonTop":["Injection-site erythema","Irritability","Injection-site swelling","Injection-site pain","Pyrexia"]}}}